LITS 10 Year Annualized Return and Average Annual Return

The LITS 10 year annualized return is -0.81% with dividends reinvested through 07/17/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows LITS average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
LITS Average Annual Return Chart 10 Years
Growth of $10,000.00
With Dividends Reinvested Into LITS

Also see:
• LITS stock yearly return 2016
• LITS stock yearly return 2017
• LITS stock yearly return 2018
• LITS stock yearly return 2019
• LITS stock yearly return 2020
• LITS stock yearly return 2021
• LITS stock yearly return 2022
• LITS stock yearly return 2023
• LITS stock yearly return 2024
• LITS stock yearly return 2025
• LITS YTD return
Average Annual Return Benchmarks
Compare LITS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
LITS Share Performance
LITS Average Annual Return Table 10 Years
Start date: 07/20/2016
End date: 07/17/2026
Start price/share: $1.38
End price/share: $0.99
Starting shares: 7,246.38
Ending shares: 9,311.71
Dividends reinvested/share: $1.75
Total return: -7.81%
LITS Average Annual Return: -0.81%
Starting investment: $10,000.00
Ending investment: $9,219.10


LITS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Lite Strategy Inc
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Co.'s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib has completed a Phase I trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) in combination with the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (marketed as Venclexta). The LITS average annual return 10 years is shown above.

The Average Annual Return on the LITS average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether LITS average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the LITS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
LITS Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree LITS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Lite Strategy (LITS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

LLY Average Annual Return
LMAT Average Annual Return
LMNX Average Annual Return
LNSR Average Annual Return
LNTH Average Annual Return
LONA Average Annual Return
LPCN Average Annual Return
LQDA Average Annual Return
LRMR Average Annual Return
LSTA Average Annual Return
More Healthcare companies »
What has the average annual return been for LITS over the past ten years?
✔️Accepted answer: The ten year LITS average annual return has been -0.81% with dividends reinvested.

When you say 'with dividends reinvested' what does that mean?
✔️Accepted answer: That means that each time the stock goes ex-dividend, the average annual return calculation then factors in how that dividend amount could have been reinvested into more shares of LITS at the then-current price — often this is referred to as 'compounding' and is very important when considering average annual return over a long period like a full decade.

What start date was used in your LITS average annual return calculation?
✔️Accepted answer: The start date was 07/20/2016.

What end date was used in your LITS average annual return calculation?
✔️Accepted answer: The end date was 07/17/2026.

If I had invested $10,000 into LITS ten years ago, how much would I have today?
✔️Accepted answer: With dividends reinvested, as of 07/17/2026, you would have $9,219.10.

What does that work out to on a total return basis?
✔️Accepted answer: The LITS ten year total return ending 07/17/2026 works out to -7.81%.


Also see:
• LITS stock yearly return 2016
• LITS stock yearly return 2017
• LITS stock yearly return 2018
• LITS stock yearly return 2019
• LITS stock yearly return 2020
• LITS stock yearly return 2021
• LITS stock yearly return 2022
• LITS stock yearly return 2023
• LITS stock yearly return 2024
• LITS stock yearly return 2025
• LITS YTD return
 

LITS 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.